Story perspectives

Sarepta CEO Doug Ingram Retires Amid Family Health Struggles

2/27/2026

Summary

Story summary

Doug Ingram, the chief executive officer of Sarepta Therapeutics, will retire by the end of the year after nearly a decade leading the biotech firm focused on Duchenne muscular dystrophy.
His retirement follows personal challenges, as two family members were diagnosed with myotonic dystrophy.
Sarepta achieved four therapeutic approvals during Ingram's leadership.
The company faced safety concerns linked to its gene therapy.
A search for Ingram's successor is underway.

1 of 1

Story summary

Doug Ingram, the chief executive officer of Sarepta Therapeutics, will retire by the end of the year after nearly a decade leading the biotech firm focused on Duchenne muscular dystrophy.
His retirement follows personal challenges, as two family members were diagnosed with myotonic dystrophy.
Sarepta achieved four therapeutic approvals during Ingram's leadership.
The company faced safety concerns linked to its gene therapy.
A search for Ingram's successor is underway.